1Q EARNINGS: BMS sees sales slide, plans nivolumab rolling BLA
This article was originally published in Scrip
Bristol-Myers Squibb reported a 1% drop in first quarter revenue to $3.81bn, but investors and analysts were more focused on the company's research and development pipeline – namely, the cancer immunotherapy nivolumab – than its commercial portfolio.
You may also be interested in...
Private Company Watch: Neuron23, Neurogene and Locanabio each raised $100m or more, highlighting increased investor interest in novel approaches to neurological diseases. Also, CRO dMed raised $100m and MinervaX brought in $57m for its vaccine to protect newborns.
Bioverativ revealed its first transaction since spinning out from Biogen with the acquisition of True North for $400m plus up to $425m in milestone payments. The deal gives Bioverativ a clinical asset, helping to fill the gap between preclinical programs and commercial products in its R&D pipeline.
New product sales doubled from $161m in the first quarter to $344m in Q3 and the R&D pipeline advancing as planned ahead of generic competition for Revlimid, which will begin to launch in 2022.